

NE/I
D.K.
ent 9/25/07

The following listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-24. (Cancelled):

36.25. (Currently Amended): A method for treating a HCV ~~Flaviviridae viral~~ infection in a host comprising administering to the host a therapeutically effective amount of at least one compound according to any one of claims ¹60, ²⁹96, ³¹102 and ³²103 ~~claim 50~~.

31.26. (Currently Amended): A method according to claim ³⁶25, wherein said pharmaceutically acceptable salt is a sodium salt.

27. (Cancelled):

28. (Cancelled):

29. (Cancelled):

30. (Cancelled):

31. (Cancelled):

32. (Cancelled):

33. (Cancelled):

34. (Cancelled):

35. (Cancelled):

36. (Cancelled):

37. (Cancelled):

40 38. (Previously Presented): A method according to Claim 64, wherein said compound is a sodium salt.

39. (Cancelled):

40. (Cancelled):

41. (Currently Amended): A method for treating a HCV infection in a host comprising administering to the host a therapeutically effective amount of at least one compound according to Claim ~~60~~ 25, further comprising administering at least one additional agent chosen from interferon α , ribavirin, silybum marianum, interleukine-12, amantadine, ribozyme, thymosin, N-acetyl cysteine, and or cyclosporin.

42. (Cancelled):

43. (Cancelled):

44. (Cancelled):

45. (Cancelled):

46. (Cancelled):

47. (Cancelled):

48. (Cancelled):

49. (Cancelled):

50. (Cancelled):

51. (Cancelled):

52. (Cancelled):

53. (Cancelled):

54. (Cancelled):

55. (Cancelled):

56. (Cancelled):

57. (Cancelled):

58. (Cancelled):

59. (Cancelled):

60. (Currently Amended): A compound selected from:

3-[(4-METHYL-CYCLOHEXANECARBONYL)-(4-OXO-CYCLOHEXYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID;

3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID;

3-[(4-HYDROXYIMINO-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID;

3-[(4-METHOXYIMINO-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID;

3-[(4-METHOXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID;

5-(4-FLUORO-PHENYL)-3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID;
 5-(3-FLUORO-PHENYL)-3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID;
 5-(4-CHLORO-PHENYL)-3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID;
 3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-(4-METHOXY-PHENYL)-THIOPHENE-2-CARBOXYLIC ACID;
 5-(4-CYANO-PHENYL)-3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID;
 3-[(4-CARBOXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID;
 5-(3,4-DIFLUORO-PHENYL)-3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID;
 5-(4-ACETYL-PHENYL)-3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID;
 3-[(4-HYDROXY-4-METHYL-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID;
~~3-[(4-HYDROXY-4-METHYL-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID;~~
 3-[(3-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID;
 and
 pharmaceutically acceptable salts thereof.

61. (Cancelled):

62. (Cancelled):

63. (Cancelled):

39 ~~64~~. (Currently Amended): A method for inhibiting or reducing the activity of ~~HCV a flaviviridae viral~~ polymerase in a host comprising administering to said host a therapeutically effective amount of at least one compound according to any one of claims 60, 96, 102 and 103 ~~claim 60~~.

65. (Cancelled):

66. (Cancelled):

34 ~~67~~. (Currently Amended): A pharmaceutical composition comprising at least one compound according to any one of claims ¹60, ²⁷96, ³¹102 and ³²103 ~~claim 60~~ and at least one pharmaceutically acceptable carrier or excipient.

2 ~~68~~. (Previously Presented): A compound according to claim 60, wherein said compound is 3-[(4-METHYL-CYCLOHEXANECARBONYL)-(4-OXO-CYCLOHEXYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

3 ~~69~~. (Previously Presented): A compound according to claim 60, wherein said compound is 3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

4 ~~70~~. (Previously Presented): A compound according to claim 60, wherein said compound is 3-[(4-HYDROXYIMINO-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC

ACID, or a pharmaceutically acceptable salt thereof.

6 71. (Previously Presented): A compound according to claim 60, wherein said compound is 3-[(4-METHOXYIMINO-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

6 72. (Previously Presented): A compound according to claim 60, wherein said compound is 3-[(4-METHOXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

73. (Cancelled):

7 74. (Previously Presented): A compound according to claim 60, wherein said compound is 5-(4-FLUORO-PHENYL)-3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

8 75. (Previously Presented): A compound according to claim 60, wherein said compound is 5-(3-FLUORO-PHENYL)-3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

9 76. (Previously Presented): A compound according to claim 60, wherein said compound is 5-(4-CHLORO-PHENYL)-3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

10 77. (Previously Presented): A compound according to claim 60, wherein said compound is 3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-(4-METHOXY-PHENYL)-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

11 78. (Previously Presented): A compound according to claim 60, wherein said compound is 5-(4-CYANO-PHENYL)-3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

12 79. (Previously Presented): A compound according to claim 60, wherein said compound is 3-[(4-CARBOXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

13 80. (Previously Presented): A compound according to claim 60, wherein said compound is 5-(3,4-DIFLUORO-PHENYL)-3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

14 81. (Previously Presented): A compound according to claim 60, wherein said compound is 5-(4-ACETYL-PHENYL)-3-[(4-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

15 82. (Previously Presented): A compound according to claim 60, wherein said compound is 3-[(4-HYDROXY-4-METHYL-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

16 83. (Previously Presented): A compound according to claim 60, wherein said compound is 3-[(3-HYDROXY-CYCLOHEXYL)-(4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

17 84. (Previously Presented): A compound according to claim 60, wherein said compound has a monosubstituted-cyclohexyl group attached to the amino and the monosubstituent group of the cyclohexyl group attached to the amino is in the trans position relative to the amino.

18 85. (Previously Presented): A compound according to claim 84, wherein said compound has a 3-substituted-cyclohexyl group or 4-substituted-cyclohexyl group attached to the amino.

19 86. (Previously Presented): A compound according to claim 85, wherein said compound has a 4-hydroxy-cyclohexyl group attached to the amino.

20 87. (Previously Presented): A compound according to claim 60, wherein said compound has a monosubstituted-cyclohexyl group attached to the amino and the monosubstituent group of the cyclohexyl group attached to the amino is in the cis position relative to the amino.

21 88. (Previously Presented): A compound according to claim 87, wherein said compound has a 3-substituted-cyclohexyl group or 4-substituted-cyclohexyl group attached to the amino.

22 89. (Previously Presented): A compound according to claim 88, wherein said

compound has a 4-hydroxy-cyclohexyl group attached to the amino.

23 90. (Previously Presented): A compound according to claim 84, wherein said compound has a monosubstituted-cyclohexyl group attached to the carbonyl and the mono-substituent of the cyclohexyl group attached to the carbonyl is in the trans position relative to the carbonyl.

24 91. (Previously Presented): A compound according to claim 85, wherein said compound has a monosubstituted-cyclohexyl group attached to the carbonyl and the mono-substituent of the cyclohexyl group attached to the carbonyl is in the trans position relative to the carbonyl.
















25 92. (Previously Presented): A compound according to claim 86, wherein said compound has a monosubstituted-cyclohexyl group attached to the carbonyl and the mono-substituent of the cyclohexyl group attached to the carbonyl is in the trans position relative to the carbonyl.






26 93. (Previously Presented): A compound according to claim 90, wherein said compound has a 4-hydroxy-cyclohexyl group attached to the carbonyl.

27 94. (Previously Presented): A compound according to claim 91, wherein said compound has a 4-hydroxy-cyclohexyl group attached to the carbonyl.







28 95. (Previously Presented): A compound according to claim 92, wherein said compound has a 4-hydroxy-cyclohexyl group attached to the carbonyl.





2996. (Previously Presented): A compound according to claim 85, wherein said compound is selected from compounds of the following formulas and pharmaceutically acceptable salts thereof:





30 97. (Previously Presented): A compound according to claim 96, wherein said compound is selected from compounds of the following formulas and pharmaceutically acceptable salts thereof:





98. (Cancelled):

99. (Cancelled):

100. (Cancelled):

101. (Cancelled):

3 | ~~102.~~ (Previously Presented): A compound according to claim 69, wherein said compound is 3-[(*trans*-4-HYDROXY-CYCLOHEXYL)-(*trans*-4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC ACID, or a pharmaceutically acceptable salt thereof.

3 | ~~103.~~ (Currently Amended): A compound according to claim 69, wherein said compound is 3-[(*cis trans*-4-HYDROXY-CYCLOHEXYL)-(*trans cis*-4-METHYL-

CYCLOHEXANECARBONYL)-AMINO]-5-PHENYL-THIOPHENE-2-CARBOXYLIC
ACID, or a pharmaceutically acceptable salt thereof.

Ex amended.
104. (New): A method according to Claim 41, further comprising administering at least one additional agent chosen from interferon α and ribavirin.

³⁵ 105. (New): A composition according to claim ³⁴ 67, wherein said compound is a sodium salt.

³³ 106. (New): A compound according to any one of claims any one of claims 60, 96, 102 and 103, wherein said compound is a sodium salt.

³⁸ 107. (New): A method according to Claim ³⁶ 25, wherein said HCV of genotype 1b.